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Abstract
Along the transformation process, cells accumulate DNA aberrations, including mutations, translocations, amplifications,
and deletions. Despite numerous studies, the overall effects of amplifications and deletions on the end point of gene
expression—the level of proteins—is generally unknown. Here we use large-scale and high-resolution proteomics
combined with gene copy number analysis to investigate in a global manner to what extent these genomic changes have a
proteomic output and therefore the ability to affect cellular transformation. We accurately measure expression levels of
6,735 proteins and directly compare them to the gene copy number. We find that the average effect of these alterations on
the protein expression is only a few percent. Nevertheless, by using a novel algorithm, we find the combined impact that
many of these regional chromosomal aberrations have at the protein level. We show that proteins encoded by amplified
oncogenes are often overexpressed, while adjacent amplified genes, which presumably do not promote growth and
survival, are attenuated. Furthermore, regulation of biological processes and molecular complexes is independent of
general copy number changes. By connecting the primary genome alteration to their proteomic consequences, this
approach helps to interpret the data from large-scale cancer genomics efforts.
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Introduction
Chromosomal aberrations are a hallmark of cancer cells.
During transformation cells lose cell-cycle control and fidelity of
DNA replication causing multiple changes in DNA copy numbers
[1,2]. Although chromosomal aberrations are associated with
transformation, changes in DNA copy number can cause growth
defects rather than cell growth [3,4]. Therefore transformation
requires specific genomic changes that enable tolerance to
genomic instability and promote growth and survival. The identity
of these specific altered genes that enable transformation is still
unknown, and great efforts are made to achieve a better
understanding of these gene changes and their effects. Techno-
logical developments in recent years have allowed high resolution
genomic analysis using SNP arrays, and large scale projects have
mapped the gene copy number changes in thousands of tumor
samples [5,6]. Another major step necessary for the interpretation
of the biological significance of such studies that is missing so far is
the analysis of the consequences of these alterations: to what extent
they affect protein expression. This in turn would allow
investigation and interpretation of potential biological function.
Several studies have shown high correlation between the
amplifications and deletions and changes in mRNA levels and
were therefore able to predict amplifications and deletions based
on global transcript measurements [7–11]. Still, only a few
amplifications were associated with oncogenes, and some deletions
with tumor suppressors, while the majority of these alterations
could not be associated with known tumor promoting activities
[5,6]. Furthermore, the effects of co-amplifications and deletions of
genes in the same regions as known tumor-related genes, are yet to
be discovered. A priori it would be possible that proteins encoded
in a given amplicon are uniformly overexpressed in accordance
with genome copy number or alternatively, that the expression
levels only of selected or none of the proteins changes. These
different scenarios have very different implications when trying to
assess potential biological and oncological effects of a given
amplicon detected in a somatic cancer genome.
For better understanding of the general output of chromosomal
changes, the protein level therefore has to be globally examined.
Such knowledge can be crucial as it can suggest novel potential
drivers of transformation and, as already shown in specific cases in
the past, help determine treatment modalities and prognosis
[12,13]. To compare proteomic to genomic alterations in a
system-wide manner deep coverage of the proteome is essential as
it maximizes the chance to detect and accurately quantify the
proteins expressed from amplified or deleted regions. Stable
Isotope Labeling by Amino Acids in Cell Culture (SILAC) is an
accurate method for quantitative mass-spectrometry based pro-
teomics [14,15]. Recent advances in SILAC-based proteomics
using high resolution mass spectrometry [16,17] enabled accurate
proteome coverage of the complete yeast proteome [18] and large
proportions of the mammalian proteome [19]. Based on these
developments, we could now compare cancer cell lines containing
multiple chromosomal alterations and normal diploid epithelial
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detected by SNP arrays. This accurate analysis enabled us to find
the output of thousands of genes with varying gene dosage, and
thereby estimate their regulation and their potential impact.
Results/Discussion
In-depth proteomic analysis of breast cancer cells and
comparison to SNP array copy number data
To study the effects of genomic alterations on the protein level,
we performed quantitative proteomic analysis of two aneuploid
breast cancer cell lines and normal diploid cells. We SILAC-
labeled the MCF7 breast cancer cell line with heavy lysine and
arginine to serve as internal standard for quantification. The lysate
of the labeled cells was combined with normal mammary epithelial
cells (HMEC) or with two breast cancer cell lines - HCC2218,
derived from a patient with Stage III ductal carcinoma and
HCC1143, derived from a patient with Stage II ductal carcinoma
(Figure 1). We analyzed each proteome mixture by enzymatic
digestion and isoelelectric focusing of the resulting peptides
followed by online liquid chromatography mass spectrometry on
hybrid linear ion trap Orbitrap mass spectrometers. In total we
identified and quantified 72,239 SILAC peptide pairs at 99%
confidence. Quantification of cancer cell lines against normal cells
was computed as the ‘ratio-of-ratios’ of each proteome against the
internal MCF7 SILAC standard, requiring at least two quantifi-
cation events per protein in each experiment. From biological
triplicates, we identified and quantified 6,735 proteins (an average
of more than 5,000 quantified proteins per cell line).
For the analysis of chromosomal aberrations, we mapped the
copy number changes in the genome of HCC2218, HCC1143
and HMEC with SNP arrays (Affymetrix- Genome-wide Human
SNP Array 6.0; Figure 1). Similar to the proteome analysis, we
calculated the ratios of the signal in the cancer cell lines
compared to the diploid control cells, then matched the
chromosomal position with the gene, and determined the change
in copy number as the median of the signals of all the probes
annotated to the same gene. We matched between the proteins
and the genomic data based on the gene name, enabling direct
comparison of the level of almost every identified protein and its
encoding gene.
A density plot of gene copy number of the HMEC indicates that
these cells are diploid and therefore can serve as a normal control
(Figure 2A). We normalized the proteomic and the genomic data
of HCC2218 and HCC1143 cells to the control cells. Overall
correlation between the change in gene copy number and the
change in protein level determined in this way was low (0.22 for
HCC2218 and 0.28 for HCC1143 cells). Only 4.8% and 7.8% of
the protein level changes were determined by the copy number
changes of the genes, significantly less than the percentage of
transcriptome changes explainable by genome differences
[9,10,20,21]. This suggests that there is a tighter coupling between
gene copy numbers and transcript changes than between gene
copy numbers and protein level changes. The remaining changes
of protein levels are presumably caused by other mechanisms of
regulation of protein expression.
Figure 1. Measuring proteome and genome changes in cancer
versus normal cells. For proteomic analysis lysates of each of the
non-labeled cells (HMEC, HCC1143 and HCC2218) were mixed with
lysate of SILAC-labeled MCF7 cells. Proteins were trypsin-digested and
analyzed by LC-MS using high resolution mass spectrometry. For
genomic analysis, genomic DNA was isolated from HMEC, HCC1143 and
HCC2218 cells and hybridized with a SNP arrays.
doi:10.1371/journal.pgen.1001090.g001
Author Summary
In the course of cancer development, cells lose regulation
of the cell cycle and quality control of DNA replication. As a
result, many genomic alterations accumulate, among them
amplifications and deletions of chromosomal regions of
varying sizes. Oncogenes that drive transformation often
reside in amplified regions, while tumor suppressors are
deleted, yet for thousands of genes the effect of altering
gene copy number is unknown. Since only genomic
alterations that ultimately affect protein levels can have
functional importance, a global proteomic approach that
directly measures such changes is desirable. Here, we
examined output of chromosomal alterations on the
proteins in a system-wide manner. We analyzed the global
protein expression of cancer cells compared to normal
cells using mass-spectrometry–based quantitative proteo-
mics and quantified a large part of the expressed
proteome. We compared the protein data to genomic
data and matched changes in gene copy number to
protein expression level changes for each gene. Overall,
gene copy number changes explain only a few percent of
observed protein expression changes. Knowledge of when
genomic and proteomic changes correlate may help in a
better understanding of regulatory mechanisms in tumor
development.
Global Proteomic Analysis of Genomic Alterations
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that the genome is distributed around integer values corresponding
to 0, 1, 2, 3, 4 gene copies (Figure 2B and 2C). The distribution of
the proteins encompassed many higher fold changes and was
much less structured. Interestingly, many genes with higher than
diploid copy number nevertheless have reduced protein expression
and for many genes loss of one copy still resulted in increased
protein expression compared to normal cells (rectangles in
Figure 2B).
Prediction of chromosomal aberration based on
proteomic data
Many chromosomal changes can be inferred from mRNA data
[7–9]. Given the depth and accuracy of our proteome measure-
ment, we wanted to see whether despite the low overall
correlation, gene amplifications and deletions can also be directly
inferred from proteomic data and to find region-related proteomic
changes. We developed a genome profiling algorithm that
examines the correlation between the expression levels of proteins
that are adjacent in a given chromosomal location. This algorithm
orders proteins on each chromosome and checks for significant
regional deviations of their log ratios from zero. For that purpose
windows encompassing various numbers of adjacent proteins are
moved along the chromosome, and the deviation of the window
mean from zero is tested by one-sample t-test. A p-value is
determined for each window size ranging from 3 proteins to the
whole chromosome. The final amplification or deletion profile is
then calculated from the window medians of all windows in which
the average value differs significantly from zero. At each position
each intersecting significant window is considered and among
those the value that deviates most from zero is chosen. This value
is reported in the amplification/deletion profile at this position.
After genome profiling, the correlation between the calculated
change in protein amounts at each genome position and the
corresponding change in gene copy number was greatly increased
(0.64 and 0.59 for HCC2218 and HCC1143, respectively). We
plotted the calculated proteomic values against their chromosomal
location to visualize amplifications and deletions along the
chromosomes (Figure 3A and 3C). The genome profiling
algorithm predicted and localized numerous aberrations. In
HCC2218 cells we found very high level amplification in
chromosomes 1 and 17, and lower amplifications in chromosomes
5, 7, 8, 14, 16, 19, 20, 21. We found only two small deletions in
chromosomes 1 and 3. In HCC1143 cells we predicted
amplifications in chromosomes 1, 6, 8, 10, 19, 20, 21 and 22,
and deletions in chromosomes 4, 5, 8, 12, 16 and 17.
To examine whether our predictions were correct despite the
low correlation between genome and proteome, we performed a
similar alignment of the genomic data. We plotted the smoothed
data of the SNP array (normalized to the control cells) directly
according to the genomic location. Although not all aberrations
had a detected proteomic output; remarkably, in each of the
predicted locations, we indeed found a matching change in the
SNP array data (Figure 3B and 3D). Thus accurate proteome
measurements can indeed detect genome copy number changes,
via the regional effects on protein expression level changes.
Furthermore, these predicted changes agree with well known
breast cancer genomic alterations, such as gains in chromosome
1q, 8q, 16p, 17q, 20q and losses in chromosomes 4q, 8p [22,23].
Figure 2. Comparison of gene copy number change to protein
change. (A) Density plot of Affymetrix smooth signal in the HMEC
control cells. A small peak at zero was removed, which was caused by
probes for the Y-chromosome, which was absent in this female cell line.
(B,C). Scatter plot of gene copy number in HCC2218 cells (B) or
HCC1143 cells (C) normalized to the copy number of genes in HMEC vs.
the ratio of the proteins in HCC1143 or HCC2218 cells relative to HMEC.
The rectangle in the upper left part of (B) encloses genes with increased
gene copy compared to control cells but decreased protein expression.
The rectangle in the lower right contains single copy genes with
increased protein expression compared to control cells.
doi:10.1371/journal.pgen.1001090.g002
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While the correlation between the gene copy number and the
proteins was very low, it was still possible that the altered genes
would globally affect specific pathways and processes, to confer a
growth advantage to the aneuploid cells. We comprehensively
analyzed each process to determine to what extent it is regulated
on the protein level or on the genomic level. We developed a two-
dimensional annotation distribution analysis tool (see Materials
and Methods), to determine protein categories with significant co-
regulation in the combined space of gene copy number and
protein changes. We examined gene-ontology (GO) categories,
KEGG pathways, protein complexes annotated in the CORUM
database and distribution of genes to chromosomes (Figure 4). The
only categories changing at the genome level were the chromo-
Figure 3. Genome profiling of genomic and proteomic data. Protein ratios were averaged according to their localization using the genome
profiling algorithm (Materials and Methods). Calculated ratios of proteins in HCC2218 (A) or HCC1143 (C) versus HMEC are plotted against their
chromosomal location. Smoothed data of gene copy number in HCC2218 (B) or HCC1143 (D) normalized to the control cells are plotted against their
chromosomal location. Each color represents a different chromosome.
doi:10.1371/journal.pgen.1001090.g003
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overall effect on the proteome level. Almost all other statistically
significant categories, including GO, KEGG and CORUM are
distributed horizontally along the proteome direction, indicating
that they cannot be directly attributed to broad changes in gene
dosage (Table S1). As an example, Figure S1 illustrates the
changes in oxidative phosphorylation genes and proteins in
HCC2218. There was a clear increase in the abundance of
proteins involved in this process, while most of the corresponding
gene copy numbers were constant (Figure S1). Moreover, there
were genes whose copy number changed, but the encoded proteins
did not change accordingly. For example NDUFB9, ATP6V1H
and ATP1C1, were amplified, and a single copy of ATP6V1B2
was deleted, but the protein levels stayed constant. In this case,
clearly the copy number of genes belonging to this process had no
effect on its functionality.
Stable protein complexes maintain constant protein
expression despite changed gene copy number and
mRNA expression
Our two-dimensional annotation analysis further highlighted a
number of protein complexes, such as the proteasome, ribosome,
spliceosome and NADH dehydrogenase complex. We found that
the proteins of these complexes always maintain equal protein
ratios, despite variation in the gene copy number of their subunits
(Figure 5A and Figure S2). Interestingly, this is strictly true for the
core complexes components, but to a lesser degree for peripheral
proteins, which can also be involved in other processes. The 20S
proteasome, which includes seven alpha and seven beta subunits,
is completely insensitive to gene dosage while the levels of the
proteins from the whole 26S proteasome vary slightly (Figure 5A
and 5B). Similarly, we found much higher variation in the
spliceosome complex than in the 17S U2 snRNP subcomplex
(Figure S2B). We further examined whether the determination of
the exact ratios of the proteins in a core complex is due to
regulation already at the level of mRNA and can be attributed to
regulation of transcription or mRNA stability, or on the protein
level and could be related to protein translation or degradation.
We measured the mRNA levels of the proteasome core complex
(seven alpha subunits and seven beta subunits) by real-time-PCR
in HCC2218 cells. In contrast to the equal protein amounts, we
found large variability in the mRNA levels of the subunits
(Figure 5C). The correlation between mRNA and genes was 0.6,
while the correlation between proteins and their corresponding
genes was 20.1. Therefore, the main regulation of the protein
amounts for this complex occurs at the protein level, rather than at
the mRNA level. In accordance with these results, it has been
shown that ribosomal subunits are synthesized in excess and those
subunits that do not assemble into the complex are degraded [24].
Our results suggest that this mechanism occurs in many molecular
complexes. For these complexes the abundance of the subunits is
regulated by the amount of the whole complex, and this regulation
is done only on the protein level.
Oncogenes are found as amplified genes encoding
overexpressed proteins
We showed above that cellular processes and molecular
machines do not obey gene dosage changes. But as primary
events in transformation, amplification of deletion of key
regulatory genes may impact the functionality of the whole
process. Indeed, oncogenes and tumor suppressors are often
amplified or deleted in the genome [5]. For such aberrations to
affect transformation, the gene copy number change must
positively correlate with a protein level change. For example,
HCC2218 cells have a known amplification of the ERBB2 gene,
and indeed our data show that the protein is .50 fold increased
compared to HMEC. We searched whether more of the amplified
or deleted genes with correlative protein level changes have known
oncogenic or tumor suppressor activities by comparing our data to
the Sanger institute ‘cancer gene census’ [25]. Among this list of
Figure 4. 2D annotation distribution. Scatter plot of normalized annotation changes on the genome level against the protein level. Calculation
of significance is detailed in the Materials and Methods section. The annotations analyzed were: chromosomes (red), Corum complex database
(orange), gene ontology cellular component (GOCC; green), gene ontology biological processes (GOBP; blue), gene ontology molecular function
(GOMF; black) and KEGG pathways (purple).
doi:10.1371/journal.pgen.1001090.g004
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various cancers, we selected those in which changes in genome
copy number positively correlated with our measured proteome
changes (Table S2). For instance, among the amplified genes we
found AKT1 and CCND1 in HCC1143 cells and we found
CDH1 to be deleted in HCC2218 cells.
We zoomed-in on the small amplicons encompassing ERBB2,
CCND1 and AKT1 to examine the effects of these amplifications
on the expression levels of adjacent genes (Figure 6). The ERBB2
amplicon is very well studied [26] and includes five genes; of these
we quantified three proteins: ErbB2, C17orf37 and Grb7, all of
which were highly over-expressed (Figure 6A). The significance of
ErbB2 and the effects of its inhibition are well known [27,28]. Its
amplification is examined routinely in the clinic and predicts
responsiveness to treatment with trastuzumab. Over-expression of
Grb7, a mediator of receptor tyrosine kinase and integrin
signaling, was also shown to correlate with tumor aggressiveness
[29]. The function of the gene-product of C17orf37 is still
unknown, but its protein overexpression along with ErbB2 and
Grb7 makes it an interesting candidate for functional studies in
breast cancer.
The amplicon surrounding CCND1 gene includes five genes –
of them we quantified four (Figure 6B). CCND1 encodes the cell-
cycle regulator Cyclin D1, whose overexpression is known to
enhance tumor growth in multiple cancer types [30–32]. The
same amplification event induced overexpression of Liprina1 and
Cortactin. Overexpression of Liprina1 may promote cell migra-
tion [33], and Cortactin overexpression was reported to be
associated with increased tumor aggressiveness [34]. In contrast,
expression of Fas-Associated protein with Death Domain, FADD,
was much lower than expected from the gene amplification.
FADD is an adaptor protein that mediates signals from death
receptors to caspase 8 during apoptosis [35]. Possibly, amplifica-
tion-induced protein overexpression has deleterious results for
cancer cells, which therefore control its overexpression.
The amplicon surrounding AKT1, an oncoprotein that
mediates cell growth and survival [36], is located at the end of
chromosome 14, and includes 11 genes. These contain NUDT14
and MTA1, which show even higher fold overexpression. MTA
(metastasis-associated protein) is involved in chromatin remodel-
ing, and its overexpression has been associated with a more
aggressive phenotype of some tumors [37]. NUDT14 is a
minimally characterized protein implicated in the regulation of
carbohydrate metabolism [38]. The high expression of these genes
suggests investigation of possible tumor-promoting role in these
cells. In contrast, four other amplified genes were not overex-
pressed as proteins and some of them were even down-regulated.
Crip2 and INF2 are actin binding proteins, suggesting a potential
role in cell adhesion and migration [39,40]. In agreement with the
opposing changes of Crip2 gene and protein levels, the promoter
of Crip2 was shown to be methylated in cancer cell lines and
animal models [41], offering a possible mechanism to eliminate
the effect of the amplification. The functions of AHNAK2 and
KIAA0284 are still unknown. Downregulation of proteins encoded
by amplified genes suggests that overexpression of these proteins
may have negative effects on the cells.
Extrapolating from the proteins with a known role in the
etiology of cancer, we created a list of potential novel regulators of
transformation. We listed the overexpressed proteins encoded by
amplified genes in HCC2218 and in HCC1143 cells (Table S3).
These proteins were upregulated as a result of gene amplification,
and their overexpression may have given a growth advantage to
these cells. In contrast, reduced expression of amplified proteins
may point to a negative effect on tumor growth. We performed
Figure 5. Distribution of proteasomal genes, proteins and
mRNA. (A) Scatter plot of global ratio distribution of genes vs. proteins
in HCC2218. The core 20S proteasome components are highlighted in
red. (B) Scatter plot with the 26S proteasome highlighted in red. (C)
Stacked plot of protein, gene and mRNA level of 14 proteasomal
subunits, normalized to the level in HMEC.
doi:10.1371/journal.pgen.1001090.g005
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ulated proteins, which may function as tumor suppressors, and the
upregulated protein, which may be important proteins for cell
growth. Functional research targeted towards these proteins could
lead to identification of novel drivers of transformation and crucial
regulatory proteins.
Figure 6. ERBB2, CCND1, and AKT1 amplicons. Zoom-in on the small amplicons surrounding ERBB2 in HCC2218 cells (A) CCND1 in HCC1143
cells (B) and AKT1 in HCC1143 (C). Fold changes in gene copy number compared to HMEC are marked with red rectangles; the fold changes in protein
level are marked with blue diamonds.
doi:10.1371/journal.pgen.1001090.g006
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We conclude that with high coverage of the proteome and high
quantification accuracy, multiple chromosomal aberrations can be
predicted directly from the proteomic data. Furthermore, proteo-
micscandeterminewhichgenesinanamplified region areexpressed
at all and which are changing at the endpoint of the gene expression
cascade – the level of the proteins. As expected, the expression of
some oncogenes and tumor suppressors is affected by gene copy
number. However, our data clearly show that in the majority of
cases, there is no direct correspondence between the gene copy
number change and the corresponding protein change. We suggest
that proteomics is a useful complement to widely employed gene
copy number analysis. It can determine if genome amplifications or
deletions have a downstream effect on the level of the protein - a
precondition for a potential impact on the transformation process.
Materials and Methods
Cell culture and SILAC labeling
Human mammary epithelial cells (HMEC) were obtained from
Lonza and cultured in mammary epithelial cell growth medium
(ECACC- Health Protection Agency). HCC1143 and HCC2218
cells were obtained from the American Type Culture Collection
(ATCC),andgrowninRPMIcontaining10%FBS.MCF7cellswere
obtained from the German Collection of Microorganisms and Cell
Cultures (DSMZ). MCF7 cells were SILAC labeled by culturing
them in DMEM where the natural lysine and arginine were replaced
by heavy isotope labeled amino acids, L-
13C6
15N4-arginine (Arg10)
and L-
13C6
15N2-lysine (Lys8). Labeled amino acids were purchased
from Cambridge Isotope Laboratories, Inc, USA. The medium was
supplemented with 10% dialyzed serum. Cells were cultured for
approximately 8 doublings in the SILAC medium to reach complete
labeling. For proteomic analysis each of the cell lines was analyzed in
biological triplicates.The firsttwo replicates were lysed with modified
RIPA buffer (50 mM Tris HCl pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1% NP40, 0.25% sodium deoxycholate and protease
inhibitors) at 4uC. Following lysis, lysates were centrifuged at
14,000 rpm at 4uC. Proteins were then precipitated over-night with
acetone, and resuspended in 8 M urea (6 M urea, 2 M thiourea).
Cells of the third replicate were lysed with a buffer containing 4%
SDS, 100 mM Tris-HCl pH 7.6 and 100 mM DTT. Lysates were
incubated at 95uC for 5 min, and then briefly sonicated.
DNA isolation and SNP arrays
Genomic DNA was isolated from the cells using QIAmp DNA
Blood Maxi Kit. DNA was hybridized with the Affymetrix
Genome-Wide Human SNP Array 6.0 according to the
manufacturer’s instructions. SNP array analysis was done in the
Microarray DNA facility at the Max Planck Institute of Molecular
Cell Biology and Genetics, Dresden. Raw files were analyzed with
‘‘Copy Number and LOH analysis’’ algorithm from the
Affymetrix Genotyping console. We used the default settings with
the HapMap270 as reference, quality assessment and regional GC
correction configuration. The ‘SmoothSignal’ column from the
Affymetrix software output was used directly for the genome
profile in Figure 3. For the comparison with the proteomic data,
we determined the copy number of the gene as the median of the
smoothed signal of the probes annotated with the corresponding
gene name. These values were normalized to the gene copy
number in the control cells, which are always diploid (Figure 2A).
Trypsin digestion
Each of the non-labeled samples (HMEC, HCC1143 or
HCC2218) was mixed at a ratio 1:1 with labeled MCF7 cells.
Two methods were used for trypsin digest. In-solution digestion
was used for the first two replicates, where cells were lysed with
RIPA buffer. Filter Aided Sample Preparation (FASP) [42] was
used when lysis was done with SDS-based buffer. For in-solution
digest, proteins were reduced by incubation with 1 mM DTT for
30 min at room-temperature, followed by alkylation with 55 mM
iodoacetamide for 30 min at room-temperature in the dark. Next,
proteins were digested with Lysyl Endopeptidase (LysC) at a
concentration of 1:50 (w/w) for three hours. Proteins were then
diluted 4 fold in water, and digested with trypsin over-night at a
concentration of 1:50 (w/w). FASP digestion was performed as
previously described [42]. Briefly, proteins were loaded on
microcon-30 kDa filters. Following two washes with urea, proteins
were alkylated with 50 mM iodoacetamide. Filters were washed
twice with urea and twice with 40 mM ammonium bicarbonate,
and digested over-night with Trypsin (1:50; w/w) at 37uC.
Peptides were desalted on Milli-SPE C18 extraction cartridges
(Millipore).
RT–PCR
mRNA was isolated from HMEC, HCC1143 and HCC2218
using PrepEase RNA Spin Kit (USB). Two micrograms of each
mRNA were reverse-transcribed using First strand cDNA
Synthesis Kit (Fermentas) with oligo-dT primers. For real-time
PCR, we used IQ SYBR-green Supermix (Biorad) on a C1000
Thermal Cycler (Biorad). Method included 40 cycles of amplifi-
cation with annealing and elongation temperature of 54uCo r
58uC. Primers for GAPDH were used for normalization. List of
primers is given below (59-39):
PSMA1:for CTGTTAAACAAGGTTCAGCCAC rev CCA-
AACACTCCTGACGCATA
PSMA2:for TGTTGGAATGGCAGTAGCAG rev TGCA-
GCCAAAAGGTCTAACA
PSMA3:for TGTTGGAATGGCAGTAGCAG rev TGCA-
GCCAAAAGGTCTAACA
PSMA4:for TCAATGAGGACATGGCTTGC rev AGGGA-
CGTTTTCCTCCAAAT
PSMA5:for GCTCACATAGGTTGTGCCATG rev CTG-
GGGTCCTTTCTCATCAA
PSMA6:for GGCTATGAGATTCCTGTGGAC rev GAAG-
CTGGTTGACTCAGTTTGTT
PSMA7:for CTTTTGAGAGTCGCGGCGGA rev CCGC-
ACTGTTCTTTCATCCTG
PSMB1:for AAGAAGGAAAGGGGGCTGTA rev TCTCT-
CTCAGCCGCAGAAAT
PSMB2:for GTGAGAGGGCAGTGGAACTC rev GTGA-
GAGGGCAGTGGAACTC
PSMB3:for CGGAATGTGTGAGTCCCTCT rev CTGGG-
AACAGGGTTAGTCCA
PSMB4:for GCCAGATGGTGATTGATGAG rev GGGC-
TTCATAGGCTACACCA
PSMB5:for ACTTCCCTTACGCAACATGG rev GCCTAG-
CAGGTATGGGTTGA
PSMB6:for GGCGGACTCCAGAACAACC rev CCAGTG-
GAGGCTCATTCAGT
PSMB7:for CTGTGTCGGTGTATGCGCCA rev GCAACA-
ACCATCCCTTCAGT
GAPDH: for TGGTATCGTGGAAGGACTCATGAC rev A-
TGCCAGTGAGCTTCCCGTTCAGC
Peptide fractionation
Peptides were separated according to their isoelectric-point
using an Agilent 3100 OFFGEL fractionator (Agilent,G3100AA)
as described previously[43]. Briefly, we used 13 cm IPG Drystrips,
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a solution containing 5% glycerol and 1:50 dilution of IPG buffer,
pH 3–10 (20 ml/well). Peptides were diluted in 5% glycerol and
IPG buffer. A total of 100 mg of peptides were loaded on each
strip. Focusing was done for 20 kVh with a miximum current of
50 mA and power of 200 mW. Fractions were acidified by adding
1% TFA, 0.5% acetic acid and 3% acetonitrile. Prior to LC-MS
analysis peptides were concentrated and desalted on Stage-
Tips[44].
LC-MS analysis
Peptides were separated by reverse-phase chromatography on
an in-house made 15 cm column (inner diameter 75 mm, 3 mm
ReproSil-Pur C18-AQ media), using a nanoflow HPLC system
(Proxeon Biosystems). HPLC was coupled on-line via a nanoelec-
trospray ion source (Proxeon Biosystems) to a LTQ-Orbitrap mass
spectrometer (Thermo Fisher Scientific). Peptides were loaded
onto the column with buffer A (0.5% acetic acid) with a flow rate
of 500 nl/min, and eluted with 90 min linear gradient at a flow
rate of 250 nl/min. After the linear gradient the column was
washed with 90% buffer B and re-equilibrated with buffer A. Mass
spectra were acquired in the positive ion mode applying a data-
dependent automatic switch between survey scan and tandem
mass spectra (MS/MS) acquisition. Samples were analyzed with a
‘top 5’ method, acquiring one Orbitrap survey scan in the mass
range of m/z 300–2000 followed by MS/MS of the five most
intense ions in the LTQ. The target value in the Orbitrap was
1,000,000 ions for survey scan at a resolution of 60,000 at m/z 400
using lock masses for recalibration[45]. Fragmentation in the LTQ
was performed by collision-induced dissociation with a target value
of 5,000 ions. Ion selection threshold was 1000 counts.
MS data analysis
Raw MS files from the LTQ-Orbitrap were analyzed by
MaxQuant[14,46] (version 1.0.14.3). MS/MS spectra were
searched against the decoy IPI-human database version 3.62
containing both forward and reverse protein sequences by the
MASCOT search engine (version 2.2.04, Matrix Science). Parent
mass and fragment ions were searched with maximal initial mass
deviation of 7 ppm and 0.5 Th, respectively. The search included
variable modifications of methionine oxidation and N-terminal
acetylation, and fixed modification of cystein carbamidomethyla-
tion. Peptides of minimum 6 amino-acids and maximum of two
missed cleavages were allowed for the analysis. For peptide and
protein identification false discovery rate (FDR) was set to 0.01. In
case the identified peptides of two proteins were shared by two
proteins (homologs or isoforms), the two proteins were reported by
MaxQuant as one protein group. Complete protein and peptides
lists are given as Table S4 and Table S5.
Genome profiling algorithm
The algorithm is applied to the log ratios between relative
protein levels of a cancer cell to a normal cell. Chromosomal
locations are assigned to proteins according to the Ensembl
annotation that is included into Uniprot. On each chromosome
the sequentially ordered proteins are checked for significant
regional deviations of their normalized log ratios from zero. For
that purpose windows encompassing various numbers of adjacent
proteins are moved along the chromosome, and the deviation of
the window mean from zero is tested with a one-sample t-test.
Window sizes range from 3 proteins to the whole chromosome in
steps of factors of square root of 2. Each log p-value was
transformed in a window-length dependent way to a posterior
error probability, applying Bayes rule to two-dimensional
histograms. To correct for multiple hypothesis testing, a false
discovery rate of 2% was applied by permutation-based estimation
on the basis of 10 randomized genomes. The final amplification or
deletion profile is then calculated from the window medians of all
windows in which the average value differs statistically significantly
from zero. At each position each intersecting significant window is
considered and among those the value is taken that deviates most
from zero. This is then the value of the amplification/deletion
profile reported at this position. To obtain copy numbers, these
values have to be exponentiated and multiplied by two. Protein
ratios and the corresponding gene copy number changes are given
in Table S6. Protein ratios after genome profiling are given in
Table S7.
Two-dimensional annotation analysis
Categorical annotation is supplied in form of Gene Ontology
(GO) biological process (BP), molecular function (MF) and cellular
component (CC) as well as participation in a KEGG pathway and
membership in a protein complex as defined by CORUM. The
chromosome of the corresponding gene was considered as an
additional protein annotation. For each annotation term proteins
are separated into two groups, one containing the proteins
annotated with this term and the other containing the comple-
ment. A two-dimensional two-sample test then finds significant
difference between the two-dimensional means of the two protein
populations. Here, the two numerical dimensions consist of log
protein ratio and log copy number ratio, but the algorithm would
apply to other data types as well. The specific test we use is a two-
dimensional version of the non-parametric Mann-Whitney test.
Multiple hypothesis testing is controlled by using a Benjamini-
Hochberg false discovery rate threshold of 5%. For categories that
are significant a two-dimensional difference score is calculated by
determining the average rank of the proteins belonging to the
category. This average rank is then rescaled to the interval
between 21 and 1. A value of 1 in one of the dimensions would
mean that all members of this category are the largest values in this
dimension, while a value of 0 means that the ranks of the members
of the category are distributed in the same way as the background
proteins, having no significant bias towards larger or smaller
values.
Supporting Information
Figure S1 Oxidative phosphorylation changes. Gene copy
number changes (A) and proteomic changes (B) in oxidative
phosphorylation proteins in HCC2218 cells. Oxidative phosphor-
ylation proteins that were identified in HCC2218 were selected
and network was established using the STRING database[47]
(Version 8.2). Graphical network was done in Cytoscape (Version
2.6.3). Colors distinguish between highly up-regulated (.3 fold;
red), up-regulated (1.6–3 fold; orange), constant (0.6–1.6 fold;
yellow), down-regulated (,0.6; green), identified but not quanti-
fied (grey).
Found at: doi:10.1371/journal.pgen.1001090.s001 (2.93 MB EPS)
Figure S2 Protein complexes. Distribution of genes versus
proteins. (A) Scatter plots of gene and protein distribution in
HCC1143. Highlighted in red are the 26S or 20S proteasomal
subunits. (B) Ratio distribution of genes and proteins in HCC1143
and HCC2218, with complexes highlighted in red.
Found at: doi:10.1371/journal.pgen.1001090.s002 (5.84 MB EPS)
Table S1 Changes of functional categories on the proteome and
genome level.
Found at: doi:10.1371/journal.pgen.1001090.s003 (0.13 MB PDF)
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copy number.
Found at: doi:10.1371/journal.pgen.1001090.s004 (0.08 MB PDF)
Table S3 Amplified and deleted genes and matching changing
proteins.
Found at: doi:10.1371/journal.pgen.1001090.s005 (0.16 MB XLS)
Table S4 Complete protein table.
Found at: doi:10.1371/journal.pgen.1001090.s006 (2.39 MB XLS)
Table S5 Peptide table.
Found at: doi:10.1371/journal.pgen.1001090.s007 (9.21 MB
XLSX)
Table S6 Merged table of protein ratios and gene copy number.
Found at: doi:10.1371/journal.pgen.1001090.s008 (1.82 MB XLS)
Table S7 Genome profiled protein ratios.
Found at: doi:10.1371/journal.pgen.1001090.s009 (1.25 MB XLS)
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